GNCA Genocea Biosciences Inc.

-0.14  -4%
Previous Close 3.65
Open 3.61
Price To Book 9
Market Cap 49,316,378
Shares 14,050,250
Volume 431,757
Short Ratio
Av. Daily Volume 864,773

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Announced September 25, 2017 that development will be ceased.
Genital herpes
Topline data did not meet endpoints - September 2015
Universal vaccine candidate against pneumococcus
Phase 1/2 initial immunogenicity data presented at ASCO June 1, 2019 - elicited T cell responses to 91% of the vaccine neoantigens administered.
GEN-009 vaccine
Various cancers

Latest News

  1. Need To Know: Genocea Biosciences, Inc. (NASDAQ:GNCA) Insiders Have Been Buying Shares
  2. Are Options Traders Betting on a Big Move in Genocea Biosciences (GNCA) Stock?
  3. Genocea Announces Proposed Public Offering of Common Stock
  4. Genocea Biosciences Rallies 50% On ASCO Presentation
  5. Put Buyers Blast Red-Hot Genocea Biosciences Stock
  6. Genocea Biosciences shares rocket 101% after biotech announces positive data from early-stage trial of cancer vaccine
  7. Genocea’s GEN-009 Vaccine Demonstrates Best-in-Class Immune Responses to ATLAS™-selected Neoantigens in Cancer Patients
  8. The Genocea Biosciences (NASDAQ:GNCA) Share Price Is Down 97% So Some Shareholders Are Very Salty
  9. Genocea’s GEN-009 Clinical Results Presentation Selected by ASCO’s Journal of Clinical Oncology® as a Top 10 Featured Immuno-oncology Abstract
  10. Edited Transcript of GNCA earnings conference call or presentation 30-Apr-19 1:00pm GMT
  11. Genocea Announces Research Collaboration with Iovance to Explore Development of Neoantigen-Targeted TIL (Tumor-Infiltrating Lymphocyte) Products
  12. Genocea Announces Positive Interim Immunogenicity Data from GEN-009 Neoantigen Vaccine Phase 1/2a Clinical Trial
  13. Genocea Biosciences: 1Q Earnings Snapshot
  14. Genocea Provides Corporate Update, Including First-Quarter 2019 Financial Results
  15. Genocea to Host Quarterly Corporate Update Conference Call & Webcast on April 30th at 9:00 am ET
  16. Genocea to Present at 18th Annual Needham Healthcare Conference
  17. Genocea Presents Data at AACR 2019 Supporting Utility of ATLAS™ Platform in Predicting Melanoma Patient Response to Immune Checkpoint Inhibitors
  18. Top Ranked Momentum Stocks to Buy for March 20th
  19. Edited Transcript of GNCA earnings conference call or presentation 28-Feb-19 2:00pm GMT
  20. Will Genocea Biosciences Continue to Surge Higher?